Dr Alex Craven

This session examines how breakthrough GLP-1 receptor agonists and novel combination therapies are transforming obesity treatment paradigms, elevating patient outcomes, reshaping clinical expectations, and establishing obesity as a medically manageable chronic disease requiring long-term pharmaceutical intervention.

Key Takeaways:

• Understanding how advanced GLP-1s and dual/triple agonists achieve superior weight loss and metabolic improvements, including their effects on appetite regulation, insulin sensitivity, and cardiovascular benefits beyond traditional interventions.

• Navigating prescribing guidelines, managing patient expectations for long-term therapy, addressing access and affordability challenges, and integrating pharmacotherapy with lifestyle interventions for optimal sustainable outcomes.

This panel examines patient selection, surgical indications, and whether current practice aligns with the evolving evidence base — drawing on perspectives from both public and private hospital settings.

Key Takeaways:

• Understanding how advanced GLP-1s and dual/triple agonists achieve superior weight loss and metabolic improvements, including their effects on appetite regulation, insulin sensitivity, and cardiovascular benefits beyond traditional interventions.

• Where current clinical habits across public and private settings diverge from the latest evidence, and what it will take to close that gap.